Combined Compression and Cooling Therapy for Taxane Chemotherapy-induced Peripheral Neuropathy in Lung Cancer

Le résumé fourni par la source

BACKGROUND/AIM: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side-effect of taxane-based treatments. This study aimed to assess the efficacy and safety of a combined compression and cooling therapy for CIPN prevention in patients with lung cancer receiving taxane-containing regimens. PATIENTS AND METHODS: We retrospectively analyzed 53 patients with advanced lung cancer treated with taxane-based chemotherapy between April 2021 and March 2023. Patients underwent compression therapy using surgical gloves and elastic stockings, combined with cooling gloves and foot ice pillows, during chemotherapy infusion. RESULTS: CIPN incidence was 20.8%, with no cases of grade ≥3 neuropathy. Paclitaxel and nab-paclitaxel showed lower CIPN rates (19.0% and 15.0%, respectively) compared to docetaxel (33.3%). No patients required chemotherapy dose reductions, and adverse events related to the therapy were mild and reversible. CONCLUSION: Combined compression and cooling therapy appears to be a safe, feasible, and non-pharmacologic strategy for reducing CIPN in taxane-treated lung cancer patients. Further prospective validation is warranted.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.